+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatic-portal infusion reduces the satiating potency of CCK-8

Hepatic-portal infusion reduces the satiating potency of CCK-8

Physiology and Behavior 44(4-5): 535-538

If a satiating effect of endogenous cholecystokinin (CCK) is produced through a circulating hormonal mechanism, then administration of exogenous CCK into the hepatic-portal vein should decrease meal size. We report here that when doses of CCK-8 are injected intraperitoneally, they are at least four times more potent at reducing food intake than equivalent doses infused into the hepatic-portal vein. Intraportally administered CCK-8 at a dose of 32 micrograms.kg-1 had an equivalent satiating potency to 4 micrograms.kg-1 administered intraperitoneally. In contrast, intraportal infusions of the putative satiety hormone, tetradecapeptide bombesin, were equally as effective as intraperitoneal injections for reducing food intake. Bombesin is apparently protected from significant hepatic uptake by its larger size. We conclude that the primary reason for the ineffectiveness of portally administered CCK-8 for reducing food intake is hepatic uptake. These findings support the hypothesis that any satiating effect of endogenous CCK-8 is likely to act primarily through a paracrine mechanism.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 001850671

Download citation: RISBibTeXText

PMID: 3237843

DOI: 10.1016/0031-9384(88)90315-0

Related references

The satiating potency of hepatic portal glucagon in rats and insulin or insulin antibodies. Physiology & Behavior 61(2): 199-208, 1997

The satiating potency of hepatic portal glucagon in rats is not affected by [corrected] insulin or insulin antibodies. Physiology and Behavior 61(2): 199-208, 1997

Failure of pulsatile infusion to increase glucagon's satiating potency. Physiology and Behavior 59(4/5): 613-616, 1996

Local anesthetic decreases satiating potency of intraduodenal infusion of fats. Society for Neuroscience Abstracts 10(1): 531, 1984

Intrameal hepatic-portal infusion of glucose reduces spontaneous meal size in rats. Physiology and Behavior 73(4): 499-507, 2001

Altered serum cytokines in hepatic and portal blood of rats at early times following portal venous infusion of semi-allogeneic cells. Immunology Letters. 49(1-2): 31-36, 1996

Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study. Cancer ChemoTherapy and Pharmacology 42(4): 341-344, 1998

A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases. European Journal of Surgical Oncology 29(5): 459-466, 2003

Pressor response to the portal infusion of angiotensin ii cardio vasc portal infusion inferior vena cava infusion hypertension. Surgery (St Louis) 62(1): 103-109, 1967

Comparison of drug uptake of colorectal hepatic metastases after hepatic artery and portal vein infusion. Proceedings American Society of Clinical Oncology Annual Meeting 5: 266, 1986

Hepatic artery versus portal vein and systemic infusion of fluorodeoxyuridine of rabbit VX-2 hepatic implants. American Journal of Surgery 157(1): 126-129, 1989

Hepatic artery vs. portal vein infusion of microbeads: a large animal pre-clinical model evaluating the intrahepatic capacity for cell infusion and imaging. Xenotransplantation 17(3): 207-214, 2010

Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. Archives of Surgery 122(11): 1273-1277, 1987

Regional infusion via hepatic artery and portal vein of fudr of rabbit vx 2 hepatic implants comparison with angiotensin modulation of tumor perfusion. Surgical Forum (Chicago) 39: 431-433, 1988